Investigational drug · Phase 2
ATV-1601
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ATV-1601"
First trial start
2026
Jul 27, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ATV-1601", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Osler Weber Rendu Disease
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ATV-1601" as an intervention, largest first.
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K MutationsActive, not recruiting
Atavistik Bio, IncIndustry
NCT07038369 · 134 participants (planned) · Start Jul 29, 2025 · Primary completion Aug 31, 2028
Drug: ATV-1601 · For: Advanced Solid Tumors; Breast Cancer; Breast Carcinoma and 24 more
Sites: Los Angeles, California; Lake Mary, Florida; Boston, Massachusetts · 8 sites in all
- Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)Pivotal-lookingRecruiting
Atavistik Bio, IncIndustry
NCT07601425 · 100 participants (planned) · Start Jul 27, 2026 · Primary completion Dec 2027
Drug: ATV-1601; Placebo · For: Hereditary Hemorrhagic Telangiectasia (HHT); Osler Weber Rendu Disease
Sites: Phoenix, Arizona; San Diego, California; Augusta, Georgia · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging novel therapies for the treatment of hereditary haemorrhagic telangiectasia.
Al-Samkari H · Lancet Haematol 2026
Also in development for Hereditary Hemorrhagic Telangiectasia (HHT)
- VAD044 L-Tartrate gelatinEngasertib, VAD044Phase 32 trials
Vaderis Therapeutics AG · Hereditary Hemorrhagic Telangiectasia, Hereditary Hemorrhagic Telangiectasia (HHT)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.